These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 17022299)

  • 1. Intensity-modulated radiation therapy and xerostomia.
    Chambers MS; Weber RS; Garden AS
    J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of salivary gland dosimetry on post-IMRT recovery of saliva output and xerostomia grade for head-and-neck cancer patients treated with or without contralateral submandibular gland sparing: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1479-87. PubMed ID: 20934262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformal and intensity modulated irradiation of head and neck cancer: the potential for improved target irradiation, salivary gland function, and quality of life.
    Eisbruch A; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Anzai Y; Marsh LH; Martel MK; Ten Haken RK; Wolf GT; Ship JA
    Acta Otorhinolaryngol Belg; 1999; 53(3):271-5. PubMed ID: 10635407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy.
    Blanco AI; Chao KS; El Naqa I; Franklin GE; Zakarian K; Vicic M; Deasy JO
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1055-69. PubMed ID: 15990009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiotherapy: is xerostomia still prevalent?
    Chambers MS; Garden AS; Rosenthal D; Ahamad A; Schwartz DL; Blanco AI; Chao KS; Morrison WH; Ang KK; Weber RS
    Curr Oncol Rep; 2005 Mar; 7(2):131-6. PubMed ID: 15717947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer.
    van de Water TA; Lomax AJ; Bijl HP; de Jong ME; Schilstra C; Hug EB; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1216-24. PubMed ID: 20732761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy.
    Münter MW; Karger CP; Hoffner SG; Hof H; Thilmann C; Rudat V; Nill S; Wannenmacher M; Debus J
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):175-84. PubMed ID: 14697436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity and compliance of subcutaneous amifostine in patients undergoing postoperative intensity-modulated radiation therapy for head and neck cancer.
    Thorstad WL; Chao KS; Haughey B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):8-12. PubMed ID: 15726516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenomenologic model describing flow reduction for parotid gland irradiation with intensity-modulated radiotherapy: evidence of significant recovery effect.
    Scrimger RA; Stavrev P; Parliament MB; Field C; Thompson H; Stavreva N; Fallone BG
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):178-85. PubMed ID: 15337554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer.
    Eisbruch A; Ship JA; Dawson LA; Kim HM; Bradford CR; Terrell JE; Chepeha DB; Teknos TN; Hogikyan ND; Anzai Y; Marsh LH; Ten Haken RK; Wolf GT
    World J Surg; 2003 Jul; 27(7):832-7. PubMed ID: 14509515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
    Jellema AP; Doornaert P; Slotman BJ; Leemans CR; Langendijk JA
    Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing.
    Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T
    Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the risk of xerostomia and mandibular osteoradionecrosis: the potential benefits of intensity modulated radiotherapy in advanced oral cavity carcinoma.
    Ahmed M; Hansen VN; Harrington KJ; Nutting CM
    Med Dosim; 2009; 34(3):217-24. PubMed ID: 19647632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sparing of the submandibular glands by intensity modulated radiotherapy in the treatment of head and neck cancer.
    Saarilahti K; Kouri M; Collan J; Kangasmäki A; Atula T; Joensuu H; Tenhunen M
    Radiother Oncol; 2006 Mar; 78(3):270-5. PubMed ID: 16564589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.